What Is Plectasin? Definition and What Research Reports

Definition

Plectasin is a small, cysteine-rich antimicrobial peptide belonging to the defensin family. It was described as a peptide antibiotic with therapeutic potential isolated from a saprophytic fungus in a 2005 report in Nature (PMID 16222292). Structurally it belongs to the cysteine-stabilised alpha-helix/beta-sheet (CSαβ) defensin fold shared with defensins from invertebrates and plants, and in the peptide literature the word "plectasin" is used both for that original fungal molecule and, loosely, for the family of engineered variants and truncated analogues derived from it, as summarised in a 2023 review covering its evolution, truncation, expression and druggability (PMID 38188573).

Where It Comes From and What Class of Molecule It Is

Plectasin is a fungal product, not a mammalian hormone or a metabolic signalling peptide. The original description characterised it as a fungal defensin recovered from a saprophytic fungus and noted its relationship to peptide antibiotics (PMID 16222292). Because it is genetically encoded and relatively short, it is normally produced for research by recombinant expression rather than chemical synthesis; researchers have reported expression systems in Pichia pastoris yeast (PMID 21558006) and in Bacillus subtilis using SUMO fusion technology with a maltose-inducible vector (PMID 26299602).

This places plectasin in a different conceptual category from the peptides most often discussed in general peptide glossaries. It is classified as an antimicrobial peptide (AMP) — a host-defence molecule whose described function is acting on microorganisms — rather than as a receptor agonist acting on human physiology.

How the Term Is Used in Peptide Research

Three usages appear across the literature:

• The parent molecule. "Plectasin" refers to the natural fungal defensin sequence first characterised in 2005 (PMID 16222292).
• A scaffold for derivatives. Papers describe "plectasin-derived peptides" or "a novel derivative of the fungal antimicrobial peptide plectasin," meaning sequence-modified or truncated analogues built on the same fold; one such derivative was reported to be active against Mycobacterium tuberculosis (PMID 30514507), and a 2023 review framed truncation as a route toward better druggability (PMID 38188573).
• A model peptide for biophysics and bioprocess work. Because it is compact, disulfide-stabilised and expressible, plectasin has been used as a test case for conformational stability modelling (PMID 31099578) and for expression-yield engineering (PMID 35503471).

What the Published Literature Reports

Antibacterial activity

The 2005 Nature paper characterised plectasin as a peptide antibiotic with therapeutic potential derived from a saprophytic fungus, and the study reported activity relevant to Gram-positive infection models (PMID 16222292). A later production-focused paper characterised recombinant plectasin expressed in Pichia pastoris as a new antimicrobial peptide with activity against Staphylococcus and Streptococcus species (PMID 21558006). Researchers have also examined the mode of action of plectasin-derived peptides against gas gangrene-associated Clostridium perfringens type A (PMID 28934314).

Combination testing with conventional antibiotics

A 2015 PLoS One study reported that combinations of β-lactam or aminoglycoside antibiotics with plectasin were synergistic against both methicillin-sensitive and methicillin-resistant Staphylococcus aureus in laboratory testing (PMID 25692771). This kind of checkerboard or time-kill work is common in antimicrobial peptide research and describes interactions in culture, not outcomes in treated patients.

Derivatives against mycobacteria

Researchers described a novel derivative of plectasin that was active against Mycobacterium tuberculosis, positioning the scaffold as a starting point for anti-tuberculosis peptide design (PMID 30514507).

Expression and manufacturing

A substantial share of the plectasin literature is bioprocess work rather than pharmacology. One study expressed plectasin in Bacillus subtilis using SUMO technology with a maltose-inducible vector (PMID 26299602), while a 2022 paper reported boosting expression levels in recombinant Pichia pastoris using 2A self-processing peptide assembly (PMID 35503471). An earlier report characterised Pichia-expressed plectasin as an antimicrobial peptide against staphylococci and streptococci (PMID 21558006). The 2023 review tied these strands together under the headings of evolution, truncation, expression and druggability (PMID 38188573).

Structure, stability and self-assembly

Because manufacturability and shelf stability matter for any peptide candidate, several groups have studied plectasin's physical behaviour. A 2019 study combined molecular dynamics simulations with NMR to assess the conformational stability of plectasin as a therapeutic peptide (PMID 31099578). A 2022 Nature Communications paper reported pH- and concentration-dependent supramolecular assembly of a fungal defensin plectasin variant into helical, non-amyloid fibrils (PMID 35672293) — a finding about how the molecule behaves in solution rather than about clinical use.

Animal production studies

Plectasin has also been investigated as a feed additive in poultry. One study examined immunomodulatory responses in plectasin-supplemented broilers raised under tropical environmental conditions (PMID 33834298), and another reported on the effect of the antimicrobial peptide plectasin on growth performance, intestinal health and immune function in yellow-feathered chickens (PMID 34250068/). These are agricultural animal-science endpoints and do not translate directly to human physiology.

Quick Reference

Plectasin Tolerability: What Studies Report

The papers cited on this page were laboratory, structural, bioprocess and animal studies; none of them reported human clinical trial safety outcomes for plectasin. The poultry studies reported production and immune-function endpoints in birds rather than adverse-event profiles applicable to people (PMID 34250068, PMID 33834298). A 2023 review discussed druggability work — truncation and expression improvements — as an ongoing development problem rather than a settled one (PMID 38188573). Plectasin is not an approved medicine, and the reports above describe research findings only.

Limits of the Evidence

• Most published activity data are in vitro or in animal infection and animal-production models, not human trials.
• Many papers study derivatives or variants, not the parent peptide, so findings are not interchangeable (PMID 30514507).
• Physical behaviour depends on conditions: one study reported assembly into helical non-amyloid fibrils that varied with pH and concentration (PMID 35672293).
• Synergy findings with β-lactams and aminoglycosides were laboratory observations against S. aureus isolates (PMID 25692771).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health condition, medication or investigational compound.

References

• Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus (Nature, 2005)
• Expression of plectasin in Pichia pastoris and its characterization as a new antimicrobial peptide against Staphyloccocus and Streptococcus (Protein Expression and Purification, 2011)
• Combinations of β-lactam or aminoglycoside antibiotics with plectasin are synergistic against methicillin-sensitive and methicillin-resistant Staphylococcus aureus (PLoS One, 2015)
• Expression of plectasin in Bacillus subtilis using SUMO technology by a maltose-inducible vector (Journal of Industrial Microbiology & Biotechnology, 2015)
• Mode of action of plectasin-derived peptides against gas gangrene-associated Clostridium perfringens type A (PLoS One, 2017)
• A novel derivative of the fungal antimicrobial peptide plectasin is active against Mycobacterium tuberculosis (Tuberculosis, 2018)
• Conformational Stability Study of a Therapeutic Peptide Plectasin Using Molecular Dynamics Simulations in Combination with NMR (The Journal of Physical Chemistry B, 2019)
• Immunomodulatory responses in plectasin-supplemented broilers under tropical environmental conditions (Tropical Animal Health and Production, 2021)
• The Effect of the Antimicrobial Peptide Plectasin on the Growth Performance, Intestinal Health, and Immune Function of Yellow-Feathered Chickens (Frontiers in Veterinary Science, 2021)
• Boosting expression level of plectasin in recombinant Pichia pastoris via 2A self-processing peptide assembly (Applied Microbiology and Biotechnology, 2022)
• pH- and concentration-dependent supramolecular assembly of a fungal defensin plectasin variant into helical non-amyloid fibrils (Nature Communications, 2022)
• Plectasin: from evolution to truncation, expression, and better druggability (Frontiers in Microbiology, 2023)